Drug Trial Radar · NCT03462498
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,008
Actual
Start
Apr 2, 2018
Primary completion
Dec 31, 2021
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Kyoto University, Graduate School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).
Conditions
- Acute Coronary Syndrome
- Acute Myocardial Infarction
- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Platelet Aggregation Inhibitors
Interventions
1-months DAPTDrug
1-month DAPT followed by 59-month monotherapy
12-month DAPTDrug
12-month DAPT followed by 48-month monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study groupTime frame: 12 months
- Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study groupTime frame: 60 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyoto University Graduate School of Medicine
Kyoto, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.